Intensive LDL lowering with evolocumab reduced first heart attack or stroke in diabetes

Mass General Brigham researchers found that the intensive cholesterol-lowering therapy evolocumab reduced the risk of a first major cardiovascular event in high-risk patients who did not have known atherosclerosis (the build-up of plaque inside…

Continue Reading

News Source: medicalxpress.com